TD Cowen raised the firm’s price target on Boston Scientific to $77 from $65 and keeps an Outperform rating on the shares. The firm beleives they are on pace to meet their 2024 and LRP guidance as they look to extend its lead over peers which validates Cowen’s bullish stance on the stock.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BSX:
- Boston Scientific receives FDA approval for Farapulse PFA System
- Wells upgrades Edwards Lifesciences, says tricuspid opportunity underappreciated
- Boston Scientific price target raised to $70 from $60 at Barclays
- Qualcomm downgraded, Cigna upgraded: Wall Street’s top analyst calls
- Boston Scientific price target raised to $63 from $55 at Deutsche Bank
